SK-MEL-31細胞
器官來源： 皮膚
ATCC Number： HTB-73?
相關**： 惡性黑色素瘤
數(shù)量： 大量
運輸方式： 凍存運輸
生長狀態(tài)： 貼壁生長
細胞形態(tài)： 上皮樣
是否是腫瘤細胞： 1
物種來源： 人
Designations: SK-MEL-31
Depositors: T Takahashi
Biosafety Level: 1
SK-MEL-31細胞Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: skin
Disease: malignant melanoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
Tumorigenic: Yes
Antigen Expression: HLA A3,A29, Bw35,B40, Cw3,Cw4, DRw4
DNA Profile (STR): Amelogenin: X
CSF1PO: 10
D13S317: 12
D16S539: 13
SK-MEL-31細胞D5S818: 11,13
D7S820: 10
THO1: 6,9
TPOX: 8,11
vWA: 16,18
Cytogenetic Analysis: modal number = 82; range = 74 to 84.
This is a hypotetra-/hypertriploid human cell line. The modal chromosome number is 82 occurring at 16% with polyploidy at 10.3%. The markers del(1)(q23), t(1q10p), del(7)(p13), t(7p18q), i(21q) and 5 others are common to all cells. They are all paired in most cells. N1 and N18 are absent, N11 is single-copied, and N6, N7, N8 and N16 are generally 4-copied (many cells also had 5 copies each for N7 and N8). The X is paired.
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1-2
PGM1, 1
PGM3, 1
Gender: female
Comments: This is one of a very extensive series of melanoma lines (see also ATCC HTB-70,ATCC HTB-71 and ATCC HTB-72) isolated by T. Takahashi and associates.
Propagation: SK-MEL-31細胞ATCC complete growth medium: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
References: 23226: Pollack MS, et al. SK-MEL-31細胞HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
23256: Carey TE, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 73: 3278-3282, 1976. PubMed: 1067619
32291: Guldberg P, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57: 3660-3663, 1997. PubMed: 9288767
